collection
https://read.qxmd.com/read/23687283/evidence-based-detection-of-pulmonary-arterial-hypertension-in-systemic-sclerosis-the-detect-study
#1
JOURNAL ARTICLE
J Gerry Coghlan, Christopher P Denton, Ekkehard Grünig, Diana Bonderman, Oliver Distler, Dinesh Khanna, Ulf Müller-Ladner, Janet E Pope, Madelon C Vonk, Martin Doelberg, Harbajan Chadha-Boreham, Harald Heinzl, Daniel M Rosenberg, Vallerie V McLaughlin, James R Seibold
OBJECTIVE: Earlier detection of pulmonary arterial hypertension (PAH), a leading cause of death in systemic sclerosis (SSc), facilitates earlier treatment. The objective of this study was to develop the first evidence-based detection algorithm for PAH in SSc. METHODS: In this cross-sectional, international study conducted in 62 experienced centres from North America, Europe and Asia, adults with SSc at increased risk of PAH (SSc for >3 years and predicted pulmonary diffusing capacity for carbon monoxide <60%) underwent a broad panel of non-invasive assessments followed by diagnostic right heart catheterisation (RHC)...
July 2014: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/23515142/tocilizumab-monotherapy-versus-adalimumab-monotherapy-for-treatment-of-rheumatoid-arthritis-adacta-a-randomised-double-blind-controlled-phase-4-trial
#2
RANDOMIZED CONTROLLED TRIAL
Cem Gabay, Paul Emery, Ronald van Vollenhoven, Ara Dikranian, Rieke Alten, Karel Pavelka, Micki Klearman, David Musselman, Sunil Agarwal, Jennifer Green, Arthur Kavanaugh
BACKGROUND: Roughly a third of patients with rheumatoid arthritis treated with biological treatments receive them as monotherapy. Tocilizumab--an inhibitor of interleukin 6 receptor signalling--has been studied as monotherapy in several clinical trials. We assessed the efficacy and safety of tocilizumab monotherapy compared with adalimumab monotherapy for patients with rheumatoid arthritis. METHODS: We did this randomised, double-blind, parallel-group, phase 4 superiority study in 76 centres in 15 countries in North and South America, Australasia, and Europe...
May 4, 2013: Lancet
https://read.qxmd.com/read/19587374/how-i-treat-the-antiphospholipid-syndrome
#3
REVIEW
Bill Giannakopoulos, Steven A Krilis
This article discusses how we approach medical decision making in the treatment of the various facets of the antiphospholipid syndrome (APS), including secondary prophylaxis in the setting of venous and arterial thrombosis, as well as treatment for the prevention of recurrent miscarriages and fetal death. The role of primary thromboprophylaxis is also discussed in depth. Great emphasis is given to incorporating the most up-to-date and relevant evidence base both from the APS literature, and from large, recent, randomized controlled trials (RCTs) of primary and secondary thrombotic prophylaxis in the general population setting (ie, the population that has not been specifically investigated for APS)...
September 3, 2009: Blood
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.